Epstein 1979.

Methods	Randomised clinical trial.
Participants	Country: UK. Number randomised: 98. Post‐randomisation dropouts: not stated. Revised sample size: 98. Mean age: not stated. Females: not stated. Symptomatic participants: not stated. AMA positive: not stated. Responders: not stated. Mean follow‐up period (for all groups): mean: 66 months. Inclusion criteria Symptom status: not stated. AMA status: not stated. Response status: not stated.
Interventions	Participants were randomly assigned to 2 groups. Group 1: D‐penicillamine (n = 61). Further details: D‐penicillamine: 600 mg/day to 900 mg/day for 12 months. Group 2: placebo (n = 37).
Outcomes	Mortality.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: information not available.
Allocation concealment (selection bias)	Unclear risk	Comment: information not available.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "The original double‐blind design of the trial was discontinued after a year because both major and minor side effects identified treated patients".
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "The original double‐blind design of the trial was discontinued after a year because both major and minor side effects identified treated patients".
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: information not available.
Selective reporting (reporting bias)	High risk	Comment: adverse events not reported.
For‐profit bias	Unclear risk	Comment: information not available.
Other bias	Low risk	Comment: no other source of bias.